Eli Lilly and Company has announced a groundbreaking collaboration with OpenAI to develop novel antimicrobials to combat drug-resistant pathogens, a growing global health threat. This partnership marks a significant step forward in the fight against antimicrobial resistance (AMR), which affects countries worldwide and disproportionately impacts low- and middle-income countries. The collaboration will leverage OpenAI’s generative AI to accelerate the discovery of novel antimicrobials and develop custom technologies to combat drug-resistant pathogens. This move supports Lilly’s earlier commitment to fighting AMR through its Social Impact Venture Capital Portfolio, which aims to provide patients with two to four new antibiotics by 2030. I believe this collaboration has the potential to revolutionize the pharma industry and deliver tangible benefits for patients worldwide.
AI-Powered Antibiotics
Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens.
1–2 minutes
TOP STORIES
Unauthorized users have gained access to Anthropic’s Mythos, raising security concerns …
Clarifai has deleted millions of photos from OkCupid amid an FTC investigation into data misuse …
Nvidia’s Vera Rubin platform is set to revolutionize AI inference with unmatched performance …
Apple’s leadership transition highlights a strategic focus on silicon for AI innovation …
Apple’s leadership changes signal a strategic shift towards AI and silicon innovation …
Tennessee’s new law restricts AI claims in mental health but may create loopholes …
